NSCLC Patient Characteristics Clinical Trial
— EPICLINOfficial title:
Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA
| Verified date | December 2012 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Saudi Arabia: Ethics Committee |
| Study type | Observational |
The study is to provide accurate, reliable information on NSCLC clinical management across MENA (Middle East North Africa) countries in order to detect unmet medical needs of this disease, it is a purely observational study; therefore patients are not assigned to a particular therapeutic strategy beforehand by a protocol. Treatment will be according to current clinical practice.
| Status | Active, not recruiting |
| Enrollment | 54 |
| Est. completion date | March 2013 |
| Est. primary completion date | March 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between April 1st 2011 and March 31 2012, for PRO sub-sample: ability to read and write since they will be asked to participate in the PRO part of the study. Selection will not be based on the disease stage of each patient, in order to avoid a selection bias Exclusion Criteria: - According to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information. |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Saudi Arabia | Research Site | Dammam | Eastern |
| Saudi Arabia | Research Site | Jeddah | Western |
| Saudi Arabia | Research Site | Qassim | Central |
| Saudi Arabia | Research Site | Riyadh | Central |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Saudi Arabia,